FDA Approves Roche’s Wilserdly Combination for Advanced Breast Cancer
Story updates
10:16:13 PM UTC
SquawkNews
FDA approves Roche’s Wilserdly (giredestrant), a next-generation oral SERD, for ER-positive, ESR1-mu
10:20:10 PM UTC
SquawkNews
FDA Approves Genentech’s WILSERDLY (Giredestrant), a Next-Generation Oral SERD, for ER-Positive, ESR1-Mutated Advanced Breast Cancer
10:24:40 PM UTC
SquawkNews
Co announces that the U.S. FDA has approved WILSERDLY (giredestrant) in combination with everolimus